Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 33
Filtrar
Mais filtros

Base de dados
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Lupus ; 27(8): 1387-1392, 2018 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-29703123

RESUMO

Objective To study the influence of Maghrebian ethnicity on lupus nephritis. Methods We retrospectively reviewed the files of a cohort of 194 patients with proliferative lupus nephritis followed in seven lupus centres belonging to three groups: Europeans living in Belgium/France (E; n = 111); Maghrebians living in Europe, in casu Belgium/France (ME; n = 43); and Maghrebians living in Morocco (MM; n = 40). Baseline presentation was compared between these three groups but complete long-term outcome data were available only for E and ME patients. Results At presentation, the clinical and pathological characteristics of lupus nephritis did not differ between E, ME and MM patients. Renal relapses were more common in ME patients (54%) than in E patients (29%) ( P < 0.01). Time to renal flare and to end-stage renal disease was shorter in ME patients compared to E patients ( P < 0.0001 and P < 0.05, respectively). While proteinuria measured at month 12 accurately predicted a serum creatinine value of less than 1 mg/dl at 7 years in E patients, this was not the case in the ME group, in whom serum creatinine at month 12 performed better. Conclusion Despite a similar disease profile at onset, the prognosis of lupus nephritis is more severe in Maghrebians living in Europe compared to native Europeans, with a higher relapse rate.


Assuntos
Imunossupressores/uso terapêutico , Falência Renal Crônica/mortalidade , Rim/patologia , Nefrite Lúpica/tratamento farmacológico , Proteinúria/etnologia , Adulto , África do Norte/etnologia , Creatinina/sangue , Europa (Continente) , Feminino , Taxa de Filtração Glomerular , Humanos , Estimativa de Kaplan-Meier , Falência Renal Crônica/etnologia , Nefrite Lúpica/complicações , Nefrite Lúpica/etnologia , Masculino , Pessoa de Meia-Idade , Curva ROC , Estudos Retrospectivos , Resultado do Tratamento , Adulto Jovem
2.
Lupus ; 27(10): 1679-1686, 2018 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-30016929

RESUMO

Purpose The purpose of this study was to evaluate the safety of antithrombotic treatments prescribed during pregnancy in patients with antiphospholipid syndrome (APS). Methods This international, multicenter study included two cohorts of patients: a retrospective French cohort and a prospective US cohort (PROMISSE study). Inclusion criteria were (1) APS (Sydney criteria), (2) live pregnancy at 12 weeks of gestation (WG) with (3) follow-up data until six weeks post-partum. According to APS standard of care, patients were treated with aspirin and/or low-molecular weight heparin (LMWH) at prophylactic (pure obstetric APS) or therapeutic doses (history of thrombosis). Major bleeding was defined as abnormal blood loss during the pregnancy and/or post-partum period requiring intervention for hemostasis or transfusion, or during the peripartum period greater than 500 mL and/or requiring surgery or transfusion. Other bleeding events were classified as minor. Results Two hundred and sixty-four pregnancies (87 prospectively collected) in 204 patients were included (46% with history of thrombosis, 23% with associated systemic lupus). During pregnancy, treatment included LMWH ( n = 253; 96%) or low-dose aspirin ( n = 223; 84%), and 215 (81%) patients received both therapies. The live birth rate was 89% and 82% in the retrospective and prospective cohorts, respectively. Adverse pregnancy outcomes occurred in 28% of the retrospective cohort and in 40% of the prospective cohort. No maternal death was observed in either cohort. A combined total of 45 hemorrhagic events (25%) occurred in the retrospective cohort, but major bleeding was reported in only six pregnancies (3%). Neither heparin nor aspirin alone nor combined therapy increased the risk of hemorrhage. We also did not observe an increased rate of bleeding in the case of a short interval between last LMWH (less than 24 hours) or aspirin (less than five days) doses and delivery. Only emergency Caesarean section was significantly associated with an increased risk of bleeding (odds ratio (OR) 5.03 (1.41-17.96); p=.016). In the prospective cohort, only one minor bleeding event was reported (vaginal bleeding). Conclusion Our findings support the safety of antithrombotic therapy with aspirin and/or LMWH during pregnancy in high-risk women with APS, and highlight the need for better treatments to improve pregnancy outcomes in APS. PROMISSE Study ClinicalTrials.gov identifier: NCT00198068.


Assuntos
Anticoagulantes/efeitos adversos , Síndrome Antifosfolipídica/tratamento farmacológico , Aspirina/efeitos adversos , Fibrinolíticos/efeitos adversos , Heparina de Baixo Peso Molecular/efeitos adversos , Inibidores da Agregação Plaquetária/efeitos adversos , Hemorragia Pós-Parto/induzido quimicamente , Adulto , Síndrome Antifosfolipídica/sangue , Síndrome Antifosfolipídica/diagnóstico , Perda Sanguínea Cirúrgica/prevenção & controle , Transfusão de Sangue , Cesárea/efeitos adversos , Quimioterapia Combinada , Feminino , França , Humanos , Hemorragia Pós-Operatória/induzido quimicamente , Hemorragia Pós-Operatória/terapia , Hemorragia Pós-Parto/diagnóstico , Hemorragia Pós-Parto/terapia , Gravidez , Estudos Prospectivos , Estudos Retrospectivos , Medição de Risco , Fatores de Risco , Fatores de Tempo , Resultado do Tratamento , Estados Unidos
3.
Lupus ; 25(7): 735-40, 2016 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-26876692

RESUMO

OBJECTIVES: Benefits of hydroxychloroquine (HCQ) use on physician reported outcomes are well documented in systemic lupus erythematosus (SLE). We assess for the first time the association and predictive value of blood HCQ levels towards health-related quality of life (HRQOL) in SLE. METHODS: Data from the PLUS study (a randomized, double-blind, placebo-controlled, multicentre study) were utilized. Blood HCQ levels were quantified by high-performance liquid chromatography along with HRQOL assessments (Medical Outcomes Study-SF-36) at baseline (V1) and month 7 (V2). RESULTS: 166 SLE patients' data were analysed. Mean (SD) age and disease duration were 44.4 (10.7) and 9.3 (6.8) years. Eighty-seven per cent were women. Mean (SD, median, IQR) HCQ concentrations in the blood at V1 were 660 (314, 615, 424) ng/ml and increased to 1020 (632, 906, 781) ng/ml at V2 (mean difference 366 units, 95% confidence interval -472 to -260, p < 0.001). No significant correlations between HCQ concentrations with HRQOL domains at V1 or V2 were noted. There were no differences in HRQOL stratified by HCQ concentrations. HCQ concentrations at V1 or changes in HCQ concentration (V2-V1) were not predictive of HRQOL at V2 or changes in HRQOL (V2-V1). CONCLUSIONS: No association of HCQ concentrations with current or longitudinal HRQOL were found in SLE.


Assuntos
Antirreumáticos/sangue , Hidroxicloroquina/sangue , Lúpus Eritematoso Sistêmico/sangue , Qualidade de Vida , Adulto , Método Duplo-Cego , Feminino , França , Humanos , Modelos Lineares , Masculino , Pessoa de Meia-Idade
4.
Ann Dermatol Venereol ; 143(10): 590-600, 2016 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-27129743

RESUMO

A causal link has long been described between estrogen and systemic lupus erythematosus activity. Contraceptive and pregnancy management is now common for lupus patients, but pregnancy continues to be associated with higher maternal and fetal mortality/morbidity in systemic lupus erythematosus patients than among the general population. Potential complications include lupus flares, obstetric complications (fetal loss, in utero growth retardation, premature birth) and neonatal lupus syndrome. Association with antiphospholipid antibodies or antiphospholipid syndrome increases the risk of obstetric complications. Anti-SSA and/or anti-SSB antibodies put fetuses at risk for neonatal lupus. Improving the outcome of such pregnancies depends upon optimal systematic planning of pregnancy at a preconception counseling visit coupled with a multidisciplinary approach. Absence of lupus activity, use of appropriate medication during pregnancy based on the patient's medical history and risk factors, and regular monitoring constitute the best tools for achieving a favorable outcome in such high-risk pregnancies. The aim of this review is to provide an update on the management of contraception and pregnancy in systemic lupus erythematosus, cutaneous lupus and/or antiphospholipid syndrome in order to reduce the risk of complications and to ensure the best maternal and fetal prognosis.


Assuntos
Lúpus Eritematoso Cutâneo/complicações , Lúpus Eritematoso Sistêmico/complicações , Complicações na Gravidez , Gravidez de Alto Risco , Anticorpos Antifosfolipídeos/sangue , Anticoagulantes/uso terapêutico , Síndrome Antifosfolipídica/complicações , Anticoncepção , Ecocardiografia , Feminino , Morte Fetal , Retardo do Crescimento Fetal/etiologia , Humanos , Recém-Nascido , Lúpus Eritematoso Cutâneo/terapia , Lúpus Eritematoso Sistêmico/congênito , Lúpus Eritematoso Sistêmico/etiologia , Lúpus Eritematoso Sistêmico/prevenção & controle , Lúpus Eritematoso Sistêmico/terapia , Período Pós-Parto , Cuidado Pré-Concepcional , Gravidez , Nascimento Prematuro/etiologia , Prognóstico , Ultrassonografia Pré-Natal
5.
Lupus ; 24(14): 1479-85, 2015 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-26163661

RESUMO

OBJECTIVES: Pericardial involvement is a frequent manifestation of systemic lupus erythematosus (SLE). Growing evidence suggests that colchicine may be useful for acute or recurrent pericarditis. We report for the first time a series of 10 consecutive cases of SLE with pericarditis treated with colchicine. METHODS: Inclusion criteria in this retrospective study were diagnosis of SLE, pericarditis and receiving colchicine. RESULTS: We included 10 consecutive cases of SLE with pericarditis treated with colchicine (nine women, mean age at the index pericarditis 35 ± 12 years). Pericarditis was the initial manifestation of SLE for two patients, whereas eight patients had SLE lasting for a median of 2.5 years (15 days to 13 years) and had received prednisone (n = 7, 2-30 mg/d), hydroxychloroquine (n = 7), azathioprine (n = 3), methotrexate (n = 2), and mycophenolate mofetil (n = 1). For six patients, pericarditis was associated with other SLE manifestations. Altogether, colchicine avoided the use (n = 2) or increase in dosage (n = 5) of steroids in seven cases; the increase in steroids dosage was minimal for two patients. Colchicine 1 mg was given for a median of 39 days (10 days to 54 months). Symptoms completely resolved after a median of 2.5 days (1-30 days) after initiation of colchicine. Colchicine was maintained or resumed in six patients to prevent recurrence, with no further relapse. CONCLUSIONS: Colchicine may be safe and effective in treating SLE pericarditis and used as a steroids-sparing agent. These preliminary results need to be confirmed in a larger study with longer follow-up.


Assuntos
Colchicina/administração & dosagem , Supressores da Gota/administração & dosagem , Lúpus Eritematoso Sistêmico/complicações , Pericardite/complicações , Pericardite/tratamento farmacológico , Adulto , Antirreumáticos/uso terapêutico , Ecocardiografia/métodos , Eletrocardiografia/métodos , Feminino , Glucocorticoides/administração & dosagem , Glucocorticoides/uso terapêutico , Humanos , Imunossupressores/uso terapêutico , Lúpus Eritematoso Sistêmico/tratamento farmacológico , Masculino , Pessoa de Meia-Idade , Ácido Micofenólico/análogos & derivados , Ácido Micofenólico/uso terapêutico , Pericardite/diagnóstico por imagem , Prednisona/administração & dosagem , Prednisona/uso terapêutico , Estudos Retrospectivos , Resultado do Tratamento
6.
Rev Med Interne ; 43(11): 645-648, 2022 Nov.
Artigo em Francês | MEDLINE | ID: mdl-36088204

RESUMO

Cardiac involvement in systemic lupus (SL) and antiphospholipid syndrome (APS) can be due to variables and involve different presentations. Pericarditis is the most common lupus manifestation and occurs in 16% to 25% of patients. While corticosteroids are usually very effective, colchicine may avoid steroids and prevent relapse. Myocarditis during SL is rare and often inaugural. They may manifest as chest pain, acute heart failure, arrhythmias or conduction disturbances, and may progress to dilated cardiomyopathy and/or permanent heart failure. Their prognosis is however generally good, even in the absence of treatment with cyclophosphamide for the less serious forms. Finally, coronary involvement in SL is most often due to atherosclerotic, thrombotic origin (generally in the context of associated APS), and exceptionally explained by coronary vasculitis. During APS, valve disease is frequent and usually asymptomatic. Thrombotic damage can be (1) coronary, typically manifesting as a myocardial infarction in a young subject with healthy coronary arteries, (2) much more rarely intracardiac, or (3) microcirculatory, generally as part of a catastrophic antiphospholipid syndrome (CAPS) leading to a multiorgan failure. Finally, iatrogenic cardiac manifestations can exceptionally be seen during treatment with cyclophosphamide or antimalarials characterized by conduction disorders and/or heart failure.


Assuntos
Síndrome Antifosfolipídica , Insuficiência Cardíaca , Lúpus Eritematoso Sistêmico , Trombose , Humanos , Síndrome Antifosfolipídica/complicações , Síndrome Antifosfolipídica/diagnóstico , Síndrome Antifosfolipídica/terapia , Microcirculação , Lúpus Eritematoso Sistêmico/complicações , Lúpus Eritematoso Sistêmico/diagnóstico , Ciclofosfamida/uso terapêutico
7.
Gynecol Obstet Fertil Senol ; 49(1): 83-88, 2021 01.
Artigo em Francês | MEDLINE | ID: mdl-33161193

RESUMO

Maternal deaths from indirect obstetric causes are the result of a pre-existing disease or condition that appeared during pregnancy without obstetric causes, but which was aggravated by the physiological effects of pregnancy. Twenty-six deaths from indirect causes related to a pre-existing pathology, excluding disease of the circulatory system or infection, were analysed by the committee of experts. Pre-existing pathology during pregnancy was documented in 13 women (asthma, n=3, genetic diseases, n=3, previous breast cancer, n=2, major sickle cell syndrome, n=2, epilepsy, n=1 and brain tumour, n=1). In 13 women, the pathology was not known before pregnancy (breast cancer, n=6, brain tumours, n=3, uterine sarcoma, n=1, cervical cancer, n=1, malignant melanoma, n=1 and acute myeloid leukaemia, n=1). For 16 women (61%), the death is related to a neoplastic pathology. Although the majority were considered inevitable for 11/16 women, 5 deaths were considered possibly preventable, the main preventable factor being a delay in diagnosis, and/or a delay in starting a specific treatment. For 10 women, the death is related to a chronic non-neoplastic pathology, known before pregnancy for 9 women, judged most often as possibly preventable, the main preventable factor being the failure of the medical team or the patient to take the pathology and/or its treatment into account. A preconception medical consultation with a specialist should be recommended to all patients with pre-existing disease. A clinical examination of the breasts is strongly recommended at the first visit and then during pregnancy.


Assuntos
Doenças Cardiovasculares , Morte Materna , Acidente Vascular Cerebral , Doenças Cardiovasculares/epidemiologia , Feminino , França/epidemiologia , Humanos , Morte Materna/etiologia , Mortalidade Materna , Gravidez , Acidente Vascular Cerebral/epidemiologia
8.
Gynecol Obstet Fertil Senol ; 49(1): 67-72, 2021 01.
Artigo em Francês | MEDLINE | ID: mdl-33197653

RESUMO

Pregnancy and postpartum represent periods at very high risk of venous thromboembolism disease which appears to extend well beyond the classic 6-8 weeks after childbirth. Pulmonary embolism (PE) is still one of the three leading causes of direct maternal death (MM) in most developed countries. Between 2013 and 2015, 23 maternal deaths were caused by a venous thromboembolic complication (VTE) (20 pulmonary embolism and 3 cerebral thrombophlebitis), representing 8.8 % of maternal deaths and a Maternal Mortality Ratio of 1.0 per 100,000 live births (95 % CI 0.6-1, 4) which is stable over the last 10 years. Regarding the timing of death, 1 death occurred after abortion, 35 % (8/23) during an ongoing pregnancy (including four before 22 WG), and 61 % (14/23) after childbirth. Among the 23 deaths from VTE, 17 % (5/23) occurred outside a healthcare center (home, street). The mean age was 32.3 and 7 women (30 %) were≥35 years old. Six patients were obese (27 %). The preventability rate is 34.8 % (compared to 50 % in 2007-2009 and 2010-2012), The preventability factors involve the inadequacy of care in 34.8 % of cases (8/23), organizational factors in one case (1/23) and a lack of interaction of the patient with the health care system in two cases (2/23). Care was considered non-optimal in 59 % of these deaths. This proportion is higher than the preventability rate because suboptimal care sometimes did not influence the final outcome.


Assuntos
Morte Materna , Embolia Pulmonar , Tromboembolia Venosa , Adulto , Feminino , Humanos , Morte Materna/etiologia , Mortalidade Materna , Gravidez , Fatores de Risco , Tromboembolia Venosa/epidemiologia
9.
Ann Rheum Dis ; 69(1): 132-7, 2010 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-19158115

RESUMO

OBJECTIVES: To assess subclinical central nervous system (CNS) involvement in primary Sjögren syndrome (pSS), by comparing standard brain MRI, in-depth neuropsychological testing and (99m)Tc-ECD brain single-photon emission computed tomography (SPECT) of patients with pSS with matched controls. METHODS: 10 women (<55 years old), with pSS defined using European-American criteria, presence of anti-SSA and/or anti-SSB antibodies and no history of neurological involvement were prospectively investigated, and compared with 10 age- and sex-matched controls. All subjects underwent, within 1 month, brain MRI, neuropsychological testing, including overall evaluation and focal cognitive function assessment, and (99m)Tc-ECD brain SPECT. RESULTS: (99m)Tc-ECD brain SPECT abnormalities were significantly more common in patients with pSS (10/10) than controls (2/10; p<0.05). Cognitive dysfunctions, mainly expressed as executive and visuospatial disorders, were also significantly more common in patients with pSS (8/10) than controls (0/10; p<0.01). Notably, between-group comparisons enabled a significant correlation to be established between neuropsychological assessment and (99m)Tc-ECD brain SPECT abnormalities in patients with pSS (r(s) = 0.49, p<0.01). MRI abnormalities in patients and controls did not differ significantly. CONCLUSIONS: Neuropsychological testing and (99m)Tc-ECD brain SPECT seem to be the most sensitive tools to detect subclinical CNS dysfunction in pSS. The strong correlation between cortical hypoperfusion in (99m)Tc-ECD brain SPECT and cognitive dysfunction suggests an organic aetiology of CNS dysfunction in pSS. These data should be confirmed in a larger study.


Assuntos
Encéfalo/diagnóstico por imagem , Transtornos Cognitivos/etiologia , Síndrome de Sjogren/psicologia , Adolescente , Adulto , Estudos de Casos e Controles , Transtornos Cognitivos/diagnóstico por imagem , Cisteína/análogos & derivados , Feminino , Humanos , Imageamento por Ressonância Magnética/métodos , Pessoa de Meia-Idade , Testes Neuropsicológicos , Compostos de Organotecnécio , Compostos Radiofarmacêuticos , Síndrome de Sjogren/diagnóstico por imagem , Tomografia Computadorizada de Emissão de Fóton Único/métodos
10.
Scand J Rheumatol ; 39(6): 498-505, 2010 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-20726682

RESUMO

OBJECTIVE: Little is known about systemic sclerosis (SSc)-related myopathy. We aimed to compare the clinical and immunological features of SSc patients with or without associated myopathy. METHODS: Forty SSc patients with myopathy, defined by myalgia or muscle weakness associated with creatine kinase (CK) more than five times the upper limit range or myopathic electromyography (EMG) or abnormal myopathology, were identified from the records of four French hospital centres. For each patient, we selected two SSc controls matched for cutaneous SSc form, sex, age at SSc onset, and disease duration. We performed a case-control study testing clinical and immunological SSc-related features for association with myopathy by conditional logistic regression. RESULTS: Muscle and SSc features of patients with myopathy did not differ significantly among the four centres of origin. Only four (10%) patients with SSc-associated myopathy had anti-polymyositis-scleroderma (PM-Scl) antibodies. Case-control univariate analysis revealed that reduced forced vital capacity (FVC) [odds ratio (OR) 3.0, 95% confidence interval (CI) 1.3-34.9], heart involvement, defined as clinical congestive heart failure, left ventricular ejection fraction (LVEF) < 60%, arrhythmia or conductive abnormalities (OR 2.9, 95% CI 1.3-6.5), and scleroderma renal crisis (OR 3.0, 95% CI 1.3-34.9) were significantly more frequent in patients with myopathy than in controls. Two autoantibodies were more frequent in patients with myopathy: anti-PM-Scl (OR 5.0, 95% CI 1.1-23.9) and anti-RNP (OR 6.9, 95% CI 1.1-64.4). Multivariate analysis retained two variables associated positively with myopathy [reduced FVC (OR 3.1, 95% CI 1.3-9.8) and heart involvement (OR 2.5, 95% CI 1.1-7.1)], while anti-centromere antibodies were associated negatively (OR 0.11, 95% CI 0.03-0.53). CONCLUSION: Heart monitoring of SSc patients with myopathy should be undertaken regularly because of the association of myocardial and skeletal myopathies in such patients.


Assuntos
Doenças Musculares/etiologia , Doenças Musculares/imunologia , Escleroderma Sistêmico/complicações , Escleroderma Sistêmico/imunologia , Adolescente , Adulto , Anticorpos Antinucleares/sangue , Anticorpos Antinucleares/imunologia , Arritmias Cardíacas/sangue , Arritmias Cardíacas/imunologia , Autoanticorpos/sangue , Autoanticorpos/imunologia , Estudos de Casos e Controles , Creatina Quinase/análise , Feminino , França , Insuficiência Cardíaca/sangue , Insuficiência Cardíaca/imunologia , Humanos , Masculino , Pessoa de Meia-Idade , Debilidade Muscular/enzimologia , Debilidade Muscular/etiologia , Polimiosite/imunologia , Insuficiência Renal/sangue , Insuficiência Renal/etiologia , Insuficiência Renal/imunologia , Estudos Retrospectivos , Volume Sistólico/imunologia , Capacidade Vital , Adulto Jovem
11.
Clin Exp Rheumatol ; 28(6): 836-41, 2010.
Artigo em Inglês | MEDLINE | ID: mdl-21205461

RESUMO

OBJECTIVES: To describe the frequency of patients with an elevated systolic pulmonary artery pressure (sPAP) estimated by Doppler echocardiography in a population of SLE patients followed in a tertiary reference centre. METHODS: A search of our Internal Medicine Department database identified 93 SLE patients followed between 1995 and 2005. Their medical records were reviewed retrospectively. The PH threshold was defined as sPAP≥35mmHg. Characteristics of PH and non-PH SLE patients were compared using Fisher's, chi-square or Wilcoxon's exact test. RESULTS: Elevated sPAP was detected in 12/93 (13%) patients. When analysing the mechanisms of PH, it was considered as secondary to specific lung involvement in 2 cases, due to severe left ventricular dysfunction in 1 patient and probably corresponding to SLE-associated PAH in the 9 remaining subjects. Univariate analyses showed that sPAP≥35mmHg was more common in Black subjects (50 vs. 20%, p=0.03), in patients with longer disease duration (14±8 vs. 9.5±8 years, p=0.049), and in patients with a history of peripheral nervous system involvement (25 vs. 4%, p=0.02), pericarditis (58 vs. 27%, p=0.04), anti-Sm (42 vs. 11%, p=0.01), and anticardiolipin antibodies (75 vs. 31% p=0.007). CONCLUSIONS: PH is a relatively common complication of SLE patients managed in tertiary care centres. Doppler echocardiography allows non-invasive detection of elevated sPAP in this population that should then benefit from gold-standard techniques including right-heart catheterisation in order to confirm the diagnosis, as well as the cause and severity of PH.


Assuntos
Pressão Sanguínea/fisiologia , Hipertensão Pulmonar/etiologia , Hipertensão Pulmonar/fisiopatologia , Lúpus Eritematoso Sistêmico/complicações , Artéria Pulmonar/fisiologia , Adulto , Determinação da Pressão Arterial/métodos , Cateterismo Cardíaco , Ecocardiografia Doppler , Feminino , Humanos , Hipertensão Pulmonar/diagnóstico por imagem , Estimativa de Kaplan-Meier , Masculino , Pessoa de Meia-Idade , Artéria Pulmonar/diagnóstico por imagem , Estudos Retrospectivos , Índice de Gravidade de Doença
12.
Ann Rheum Dis ; 68(9): 1474-7, 2009 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-19054827

RESUMO

OBJECTIVES: To describe the clinical characteristics and muscle pathological features of patients with systemic sclerosis (SSc) and myopathy and analyse their impact on muscle outcome. METHODS: Thirty-five patients with myopathy and available muscle biopsy were restrospectively investigated from the charts of four hospital centres. RESULTS: Twenty-six (74%) cases had diffuse SSc. The median time from SSc diagnosis was 5 years (range 0-23) at myopathy onset. The main myopathological features were mononuclear inflammation (63%), muscle atrophy (60%), necrosis (59%), regeneration (44%), fibrosis (24%) or microangiopathy (27%). After a median follow-up of 4.4 years, 24 patients (69%) showed complete or partial muscle remission. Only histological muscle inflammation was associated with good muscle prognosis in multivariate analysis (odds ratio 44.7, 95% CI 2.8 to 704.7). Patients without muscle inflammation had a poor response to corticosteroids (38% favourable response vs 90% in patients with inflammation). CONCLUSION: Muscle histopathology is critical in the therapeutic management of SSc-associated myopathy.


Assuntos
Doenças Musculares/etiologia , Escleroderma Sistêmico/complicações , Adulto , Biópsia , Feminino , Glucocorticoides/uso terapêutico , Humanos , Imageamento por Ressonância Magnética , Masculino , Pessoa de Meia-Idade , Músculo Esquelético/patologia , Doenças Musculares/tratamento farmacológico , Doenças Musculares/patologia , Prognóstico , Estudos Retrospectivos
13.
Rev Neurol (Paris) ; 165(5): 479-81, 2009 May.
Artigo em Francês | MEDLINE | ID: mdl-18848342

RESUMO

Severe relapses are common in neuromyelitis optica (NMO). Plasma exchanges (PE) were successfully used to treat acute demyelinating relapses resistant to corticosteroids. However, little is known about PE efficiency in NMO relapses, particularly in relation with the presence or not of specific antibodies. We here report two patients with NMO (one seropositive and one seronegative) with dramatic improvement after PE on both the optical and spinal involvement.


Assuntos
Neuromielite Óptica/terapia , Troca Plasmática/métodos , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Neuromielite Óptica/fisiopatologia , Recidiva , Medula Espinal/fisiopatologia , Resultado do Tratamento , Visão Ocular
14.
Med Mal Infect ; 39(4): 247-51, 2009 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-19303728

RESUMO

OBJECTIVE: The aim of this study was to evaluate flu vaccination rates and influencing factors in patients with systemic inflammatory diseases. METHODS: All patients presenting with a systemic inflammatory disease and taking immunosuppressants, who were hospitalized or had consulted in our internal medicine department between January 2 and 31, 2006, were included in the study. The information concerning flu vaccination was collected with a standardized form. RESULTS: One hundred and thirty-seven patients (mean age 53.1+/-17.6years; 40 [29%] male patients) were included: 39 (28%) had received flu vaccination in 2005 including 14 (16.7%) of the 84 patients with no other indication for flu vaccination than IS-induced immunodepression and 25 (47.2%) of the 53 patients with other flu vaccination indication(s) (p<0.001). The most frequent reasons for non-vaccination were: absence of physician recommendation (58%), fear of adverse effects (35%) and concern on vaccine clinical effectiveness (5%). The vaccination rate was significantly higher (49%) among patients who remembered having received a voucher from the French National Health Insurance Agency versus 18% among those who did not (OR=4.2 [95%CI, 1.92-9.19] p<0.05). This correlation remained significant after adjustment for confounding factors in a logistic regression model. CONCLUSION: Influenza-vaccination coverage is low in patients receiving immunosuppressive therapy for systemic inflammatory diseases. We have to increase the influenza-vaccination coverage in this population.


Assuntos
Terapia de Imunossupressão , Vacinas contra Influenza , Vacinação/estatística & dados numéricos , Feminino , Humanos , Imunossupressores/uso terapêutico , Inflamação/tratamento farmacológico , Masculino , Pessoa de Meia-Idade
15.
Rev Med Interne ; 39(2): 117-121, 2018 Feb.
Artigo em Francês | MEDLINE | ID: mdl-29146013

RESUMO

Chronic intervillositis is a rare condition, which is associated with severe obstetrical outcome and high recurrence rate. Obstetrical adverse events are intrauterine growth restriction, recurrent early miscarriages, intrauterine deaths and prematurity by placental insufficiency. The determination of the extension and the intensity of the chronic intervillositis are not currently standardized. High rates of recurrence have been described, but actually there is no reliable predictive biomarker. No treatment is currently validated, but the use of immunomodulatory drugs could be justified by the possible autoimmune or allo-immune origin. The treatment should be particularly discussed in patients with recurrent and severe obstetrical adverse events and in the presence of severe and massive histological lesions.


Assuntos
Doenças Placentárias/diagnóstico , Placenta/patologia , Doença Crônica , Feminino , Histiócitos/patologia , Humanos , Fatores Imunológicos/uso terapêutico , Doenças Placentárias/terapia , Gravidez , Prognóstico
16.
Gynecol Obstet Fertil Senol ; 45(12S): S71-S80, 2017 Dec.
Artigo em Francês | MEDLINE | ID: mdl-29113876

RESUMO

Maternal deaths of indirect causes result of a preexisting disease or an affection appeared during the pregnancy without any relationship with obstetrical causes, but worsened by the physiological effects of pregnancy. Among the 23 deaths of indirect cause related to a preexisiting pathology, 22 (96 %) have been analyzed by the expert comity. A known or preexisting chronic disease was documented in 16 patients (sick-cell disorder, n=3, treated epilepsy, n=3, intracerebral carvenomas, n=1, multifocal glial tumor, n=1, breast cancer, n=1, systemic lupus, n=1, diabetes mellitus, n=3, antiphospholipid syndrome, n=1). For 6 women, the pathology was unknown before the pregnancy (glioblastoma, n=2, epilepsy, n=1, Ehlers-Danlos syndrome, n=1, sick-cell disorder, n=1, breast cancer, n=1). While 6 of these deaths has been evaluated as not avoidable, 13 deaths has been considered as possibly (n=12) or certainly (n=1) preventable. The main factor of avoidability was the patient's interaction with the health system (medically non advised pregnancy, lack of adherence to treatment, for example). A pre-pregnancy medical consultation with a specialist should be recommended to all patients with preexisting chronic disease, to allow a complete information about the risks of a pregnancy, treatment adaptation if needed, better adherence and multidisciplinary follow up.


Assuntos
Morte Materna/etiologia , Complicações na Gravidez/mortalidade , Adulto , Causas de Morte , Doença Crônica , Aconselhamento , Feminino , França/epidemiologia , Humanos , Cooperação do Paciente , Cuidado Pré-Concepcional , Gravidez , Fatores de Risco
17.
Arthritis Rheumatol ; 68(4): 977-85, 2016 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-26606524

RESUMO

OBJECTIVE: To define parameters predictive of lymphoma development in patients with primary Sjögren's syndrome (SS). METHODS: A multicenter case-control survey was performed to identify predictors of lymphoma. Cases were patients who developed lymphoma after diagnosis of primary SS and were mainly recruited through the Club Rhumatismes et Inflammation network. For each case, 2 controls (matched for disease duration and age) were randomly selected among patients with primary SS and without lymphoma. Cases and controls were compared using univariate analysis and then using multivariate analysis to identify independent predictors of lymphoma. RESULTS: One hundred one patients with primary SS and lymphoma were included. Eighty-seven patients were women (86.1%), and the mean ± SD age at lymphoma diagnosis was 57.4 ± 12.6 years. The most frequent histologic type was B cell non-Hodgkin's lymphoma (NHL) in 99 of 101 patients, with marginal-zone lymphoma in 76 of the 99 patients (76.8%) including 58 (58.6%) with lymphoma of the mucosa-associated lymphoid tissue type. Lymphomas were most frequently located in the salivary glands (43 patients). A specific treatment was initiated at diagnosis in 87 patients with B cell NHL, and 61 patients (61.6%) achieved complete sustained remission after the first line of treatment. In the multivariate analysis, salivary gland enlargement, the presence of rheumatoid factor (RF), low C4, cryoglobulinemia, lymphopenia, and disease activity according to the European League Against Rheumatism Sjögren's Syndrome Disease Activity Index (excluding the lymphoma domain) were found to be predictors of lymphoma. No previous treatment for primary SS was associated with any effect on lymphoma occurrence. CONCLUSION: In addition to previously known factors predictive of lymphoma occurrence, the independent roles of RF and disease activity were demonstrated in this case-control study of primary SS-associated lymphoma. Our findings highlight the roles of chronic antigenic stimulation and disease activity in the development of this severe complication.


Assuntos
Complemento C4/imunologia , Crioglobulinemia/epidemiologia , Neoplasias Pulmonares/epidemiologia , Linfoma/epidemiologia , Linfopenia/epidemiologia , Fator Reumatoide/imunologia , Neoplasias das Glândulas Salivares/epidemiologia , Síndrome de Sjogren/epidemiologia , Neoplasias Cutâneas/epidemiologia , Adulto , Idoso , Estudos de Casos e Controles , Feminino , França/epidemiologia , Doença de Hodgkin/epidemiologia , Humanos , Leucemia Linfocítica Crônica de Células B/epidemiologia , Linfoma de Células B/epidemiologia , Linfoma de Zona Marginal Tipo Células B/epidemiologia , Linfoma Difuso de Grandes Células B/epidemiologia , Masculino , Pessoa de Meia-Idade , Análise Multivariada , Micose Fungoide/epidemiologia , Estudos Retrospectivos , Índice de Gravidade de Doença , Síndrome de Sjogren/imunologia , Reino Unido/epidemiologia
18.
Rev Med Interne ; 37(5): 307-20, 2016 May.
Artigo em Francês | MEDLINE | ID: mdl-26899776

RESUMO

PURPOSE: To develop French recommendations about the management of vaccinations, the screening of cervical cancer and the prevention of pneumocystis pneumonia in systemic lupus erythematosus (SLE). METHODS: Thirty-seven experts qualified in internal medicine, rheumatology, dermatology, nephrology and pediatrics have selected recommendations from a list of proposition based on available data from the literature. For each recommendation, the level of evidence and the level of agreement among the experts were specified. RESULTS: Inactivated vaccines do not cause significant harm in SLE patients. Experts recommend that lupus patient should receive vaccinations accordingly to the recommendations and the schedules for the general public. Pneumococcal vaccination is recommended for all SLE patients. Influenza vaccination is recommended for immunosuppressed SLE patients. Live attenuated vaccines should be avoided in immunosuppressed patients. Yet, recent works suggest that they can be considered in mildly immunosuppressed patients. Experts have recommended a cervical cytology every year for immunosuppressed patients. No consensus was obtained for the prevention of pneumocystis pneumonia. CONCLUSION: These recommendations can be expected to improve clinical practice uniformity and, in the longer term, to optimize the management of SLE patients.


Assuntos
Prova Pericial , Controle de Infecções/normas , Lúpus Eritematoso Sistêmico/complicações , Lúpus Eritematoso Sistêmico/terapia , Guias de Prática Clínica como Assunto , Adolescente , Adulto , França , Humanos , Hospedeiro Imunocomprometido , Controle de Infecções/métodos , Infecções/diagnóstico , Lúpus Eritematoso Sistêmico/diagnóstico , Lúpus Eritematoso Sistêmico/imunologia , Literatura de Revisão como Assunto , Vacinação/normas , Adulto Jovem
19.
Presse Med ; 34(16 Pt 1): 1166-75, 2005 Sep 24.
Artigo em Francês | MEDLINE | ID: mdl-16208266

RESUMO

KEY POINTS: Intravenous immunoglobulins (IVIg) are preparations of normal human IgG obtained from large pools of healthy blood donors. IVIg can be used at low doses to treat patients with primary or secondary immune deficiencies and at high doses as an immunomodulatory agent in many autoimmune and systemic inflammatory diseases, especially hematologic and neurologic diseases. Its mechanisms of action are multiple, complex, and not yet well elucidated. Adverse effects are only rarely associated with IVIg. They are well tolerated, and the risk of transmission of infectious agents appears only theoretical.


Assuntos
Imunoglobulinas Intravenosas/uso terapêutico , Doenças Autoimunes/tratamento farmacológico , Humanos , Imunoglobulinas Intravenosas/farmacologia , Imunoterapia/métodos , Controle de Infecções , Infecções/tratamento farmacológico , Inflamação/tratamento farmacológico
20.
Presse Med ; 34(14): 1023-33, 2005 Aug 27.
Artigo em Francês | MEDLINE | ID: mdl-16225258

RESUMO

The pathogenesis of different types of systemic vasculitis negative for antineutrophil cytoplasm antibodies (ANCA) and involving small or medium-sized vessels is not very well documented. During polyarteritis nodosa (PAN), which is related to hepatitis B virus (HBV) infection, as well as during cryoglobulinemic vasculitides, associated with hepatitis C virus (HCV), and probably during Henoch Schönlein purpura, histological lesions may result from the deposition of immune complexes formed from viral antigens and from antibodies responsible for the activation of the classic complement pathway and for recruitment of polymorphonuclear neutrophils. Two other mechanisms are discussed for other types of ANCA-negative systemic vasculitis: immune complex deposition and sheer stress at arterial bifurcation points. A bacterial superantigen is suspected in Kawasaki disease but remains unproved.


Assuntos
Anticorpos Anticitoplasma de Neutrófilos , Vasculite/etiologia , Vasculite/imunologia , Animais , Complexo Antígeno-Anticorpo/imunologia , Antígenos Virais/imunologia , Crioglobulinemia/imunologia , Modelos Animais de Doenças , Hepacivirus/imunologia , Hepatite B/complicações , Vírus da Hepatite B/imunologia , Hepatite C/complicações , Humanos , Vasculite por IgA/etiologia , Vasculite por IgA/imunologia , Camundongos , Síndrome de Linfonodos Mucocutâneos/etiologia , Síndrome de Linfonodos Mucocutâneos/imunologia , Neutrófilos/imunologia , Poliarterite Nodosa/etiologia , Poliarterite Nodosa/imunologia , Reologia , Vasculite/fisiopatologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA